Imaging AI in Delaware

Omniscient Neurotechnology develops AI-powered connectomic analysis software for precision brain mapping and surgical planning. The company specializes in digital brain mapping technology that generates personalized connectomes—computational maps of brain functional and structural connections—using advanced algorithms and cloud-based processing of MRI and resting-state functional MRI (rs-fMRI) data. Quicktome is their flagship platform, an automated connectomic analysis solution designed for neurosurgeons and researchers to extract actionable insights into patient-specific brain networks prior to surgery and for large-scale neural data processing in research settings. The platform supports clinical decision-making across neurologic conditions including cranial surgery, neuro-oncology, depression, Alzheimer's disease, schizophrenia, and stroke. By automating what historically required manual tractography and reducing processing time from hours to under 2 hours with minimal clinician intervention, Quicktome enables faster surgical planning while preserving critical functional brain regions. The company operates through global distribution partnerships and maintains offices in Australia (Sydney, NSW) and the United States (Atlanta). Omniscient holds SOC 2 compliance certification and patents issued by the USPTO. The technology is positioned at the intersection of neuroimaging, artificial intelligence, and cloud computing, serving both clinical and research institutions worldwide.

Amalgam Rx is a regulated digital health company specializing in Software as a Medical Device (SaMD) development. Founded in 2016 and based in Wilmington, Delaware, the company develops AI-powered, modular SaaS platforms that integrate seamlessly with electronic health records (EHR) to enhance clinical decision-making across chronic care ecosystems. The company's Medical-Grade AI™ technology supports patient identification for clinical trials, clinical decision support, digital therapeutics (DTx), caregiver engagement, and wearable device integration. Amalgam Rx's platform has facilitated over 70 million clinical decisions and currently supports nearly 10 million patients across four continents with regulatory clearance. The company partners with life sciences organizations, health plans, and healthcare providers to deliver point-of-care solutions including care guidelines, financial assistance programs, and companion products. With demonstrated FDA expertise and Manufacturer of Record (MOR) designation, Amalgam Rx emphasizes regulatory compliance, quality management systems, and global scalability across multiple markets.

ScreenPoint Medical develops Transpara Breast AI, an FDA-cleared and CE-marked artificial intelligence platform for 2D and 3D mammography. The company specializes in AI-driven breast cancer detection and clinical workflow optimization. Transpara Detection is the flagship product, engineered to assist radiologists in finding malignancies earlier while reducing reading time and workload. The platform offers vendor-agnostic compatibility with existing mammography systems (FFDM and DBT), supporting single and double reading environments. Published randomized controlled trials demonstrate a 29% increase in cancer detection and 44% reduction in radiologist workload. Transpara also offers complementary applications including Density assessment (BI-RADS-like volumetric analysis) and Temporal Comparison (prior mammogram tracking across 9 months to 6.5 years). The company serves breast imaging programs, diagnostic centers, and academic medical institutions across 30+ countries. ScreenPoint emphasizes clinical validation through peer-reviewed publications and participation in multiple prospective randomized controlled trials (MASAI, PRISM). The platform targets addressing critical healthcare challenges including radiologist shortages, staff burnout, and rising diagnostic volumes while supporting precision medicine and personalized screening protocols.

Medipixel is a medical software company specializing in artificial intelligence-driven diagnostic solutions for interventional cardiology and cerebrovascular procedures. The company develops Software as a Medical Device (SaMD) products that integrate seamlessly into cath lab workflows to provide real-time quantitative analysis of cardiovascular and cerebrovascular conditions. MPXA (Medipixel X-ray Angiography) is their flagship product—an FDA 510(k)-cleared, MFDS-certified AI platform that automatically analyzes angiographic images in approximately 1.8 seconds, supporting clinician decision-making without workflow interruption. MPXA incorporates deep learning technology for vessel segmentation, lesion analysis, and quantitative assessment, with demonstrated equivalence to OCT (optical coherence tomography) in cardiovascular procedures. MPNeuro, their cerebrovascular platform, provides 3D digital twin modeling and analysis for interventional neuroradiology, achieving Mean Absolute Percentage Error of less than 1% in quantitative assessment. Medipixel was founded in South Korea and established a U.S. subsidiary in 2023. The company has secured significant funding (Series B $12.8M in 2023) and is preparing for IPO (2024). Their solutions serve interventional cardiologists and neurointerventionalists in the United States, Korea, Southeast Asia, and Middle East markets. The company holds multiple international certifications and has won industry recognition including TIME's World's Top 400 HealthTech Companies, MedTech Innovator award, and ACC Innovation Pitch Challenge.

ORCA Dental AI (operating as CephX) is a cloud-based AI diagnostic software platform specializing in automated dental imaging analysis for orthodontists and maxillofacial imaging centers. The platform provides AI-powered cephalometric tracing and analysis, 3D CBCT segmentation, intraoral scan (IOS) processing, airway volume analysis, and integrated IOS-CBCT stitching. CephX operates as a Software-as-a-Service (SaaS) offering with subscription-based pricing ($79/month for 2D Basic plan) and web-based access requiring no software installation. The company has processed approximately 300,000 cases over 15+ years and maintains FDA clearance and HIPAA compliance. Services include automated landmark detection, teeth and bone segmentation, nerve pathway identification, root absorption detection, and customizable cephalometric analyses (over 100 generic and custom options). The platform supports multiple image formats (DICOM, 2D cephs) with cloud storage, real-time collaboration features, and downloadable reports in PDF, PowerPoint, and JPG formats. Trusted by major dental networks, imaging centers, and individual practitioners globally. The company emphasizes medico-legal compliance, continuous data backup, and technical support.

MetaOptima Technology Inc. is a dermatology-focused medical technology company specializing in intelligent skin imaging and analytics platforms. The company develops AI-powered solutions for skin cancer detection, melanoma screening, and dermatological documentation. Its primary product offerings include OptimaScan, a mobile 3D total body photography system capable of full-body imaging in under one minute with 360° rotating arm capture and 48MP resolution, integrated with AI analysis; DermEngine, an advanced cloud-based platform for skin imaging, analytics, and clinical documentation used by medical professionals globally; and MoleScope, a patient-facing skin imaging device with smartphone integration for personal skin monitoring. MetaOptima's technology leverages artificial intelligence for enhanced diagnostic accuracy and workflow efficiency in dermatology practices, surgical centers, and skin cancer screening programs. The company serves dermatologists, surgical centers, melanoma diagnostic centers, and healthcare networks across Australia, New Zealand, Canada, and internationally. Products integrate seamlessly across the company's ecosystem, enabling standardized documentation, longitudinal tracking, and AI-assisted analysis. MetaOptima has demonstrated partnerships with major healthcare organizations, research institutions, and consumer health brands including L'Oréal, La Roche-Posay, Sonic Healthcare, and Melanoma Institute Australia. The company participates in government innovation programs and attends major international medical conferences including MEDICA and EADV Congress, indicating regulatory engagement and clinical validation efforts.

Neusoft Medical Systems Co., Ltd. is a global medical imaging equipment manufacturer headquartered in Shenyang, China, specializing in diagnostic imaging systems for hospital and clinical settings. The company designs, manufactures, and distributes a comprehensive portfolio of medical imaging equipment including CT scanners (including photon-counting CT technology), MRI systems, digital subtraction angiography (DSA) systems, X-ray systems, PET/CT systems, and ultrasound systems. Recent product launches include China's first photon-counting CT scanner with NMPA approval, representing advancement in imaging resolution and reduced radiation dose. Neusoft Medical operates globally across multiple regions including Europe, Middle East, North Africa, Latin America, and Central Asia, with a focus on affordable, accessible healthcare technology. The company provides comprehensive services including global customer support, equipment servicing, advanced medical technology training through dedicated training centers, and operates imaging diagnostic centers. The company also offers MDaaS (Medical Device as a Service) solutions for flexible healthcare delivery models. Founded in 2003, Neusoft Medical maintains regulatory approvals for international markets and participates actively in major medical equipment conferences including European Congress of Radiology (ECR), China International Medical Equipment Fair (CMEF), and Arab Health. The organization emphasizes clinical performance optimization and patient outcome improvement through innovation in imaging technology and intelligent ecosystem development.